Endo recalls one lot of Edex

Published: 7-Mar-2017
Packaging Regulatory

Endo Pharmaceuticals has recalled one lot of Edex (alprostadil for injection) 10mcg to the consumer level, due to lack of sterility assurance

This product recall is due to the detection by the company of a defect in the crimp caps used in the manufacture of the subject product lot.

This defect has the potential to lead to a loss of container closure integrity, which could impact the product’s sterility assurance and may lead to serious adverse events such as infections, both localised at the site of injection and systemically.

To date, Endo has not received adverse event reports related to this recall.

Edex is a prescription only intracavernous injection indicated for the treatment of male erectile dysfunction. The recall applies to the 10mcg strength, packaged in a two pack carton.

Endo states that it takes this issue seriously and is fully committed to ensuring all of its products and packaging meet the highest quality standards.

This Product Recall is being made with the knowledge of the United States Food and Drug Administration (FDA).

  • Companies:
  • Endo Pharmaceuticals
See more

You may also like

Regulatory

Accelerating and enhancing toxicology assessments

Read more
Infographic guides users through ToxHQ’s speedy assessment features

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Primary packaging container considerations for GLP-1-based drugs This article reviews trends related to GLP-1-type pharmaceuticals and discusses considerations for fill-and-finish and primary packaging containers
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain

With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
Regulatory

Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license

The licensing deal with Chiome enhances its open innovation platform
Manufacturing

Solvent recycler SPR-200 boosts sustainability in pharma labs

Recycling up to 90% of solvent in isocratic HPLC improves lab efficiency and sustainability
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Navigating challenges and charting the future of primary packaging for parenteral pharmaceuticals

Administering parenteral medications, a cornerstone of contemporary medical practice, entails injecting the drug either beneath the skin or directly into the circulatory system, reports Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now